SYSTAAQ Diagnostic Products Receives CE Mark for Molecular Diagnostics
SYSTAAQ Diagnostic Products (https://www.systaaq.com/) has announced today that it has received CE Mark for its HBV and HCV molecular diagnostic tests for the detection and quantitation of Hepatitis B and Hepatitis C viruses respectively. By achieving certification for these test, the Prince William Science Accelerator tenant, a Virginia-based firm, can sell these tests for clinical use across Europe and other geographies that recognize the designation.
SYSTAAQ Diagnostic Products is one of the leaders in molecular diagnostics, offering a wide range of products and services in the field of molecular testing. SYSTAAQ has developed highly sensitive and specific molecular diagnostic test for a number of infectious diseases. SYSTAAQ’s HBV and HCV Real Time PCR kits are molecular tests for detection and quantitation of Hepatitis B and Hepatitis viral loads by means of Real Time PCR.
Danial Richardson, Chairman Scientific Advisory Board at SYSTAAQ said that with high sensitivity and specificity of the tests, these tests can play a transformative role in the way healthcare providers diagnose the infections at a very early stage”. The tests will soon be launched in Europe, Asia and South America.
Latest posts by Chris Frew (see all)
- Paragon Bioservices Strengthens its Commitment to World Class GMP Viral Therapy Manufacturing with the Appointment of Two Key Leadership Positions and Advanced Commitment to Quality - May 8, 2019
- Three Examples That Show Why NCI is a Goldmine of Blockbuster Technologies for Commercialization - May 7, 2019
- Ashley Nash Joins Workforce Genetics to Lead Recruiting and Employer Branding Practice - May 7, 2019